期刊
PHARMACEUTICALS
卷 14, 期 1, 页码 -出版社
MDPI
DOI: 10.3390/ph14010006
关键词
focused ultrasound; microbubbles; cancer immunotherapy; immune checkpoint inhibitors; immune-related adverse effects
资金
- SNUBH Research Fund [13-2017-010]
The development of an immune-microbubble complex (IMC) has shown promise in reducing the toxicities associated with therapeutic antibodies and enhancing efficacy when combined with focused ultrasound. This concept could potentially maximize the therapeutic potential of antibody-based treatment regimens.
Cancer immunotherapy has revolutionized the way different neoplasms are treated. Among the different variations of cancer immunotherapy, the checkpoint inhibitors targeting the programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) axis have been validated and are currently used in the clinics. Nevertheless, these therapeutic antibodies are associated with significant side effects and are known to induce immune-related toxicities. To address these issues, we have developed an immune-microbubble complex (IMC) which not only reduces the toxicities associated with the antibodies but also enhances the therapeutic efficacy when combined with focused ultrasound. The concept of IMCs could be applied to any type of antibody-based treatment regimens to maximize their therapeutic potential.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据